American Society of Clinical Oncology Clinical Practice Guidelines: The Role of Bisphosphonates in Multiple Myeloma

American Society of Clinical Oncology (ASCO) - Tập 20 Số 17 - Trang 3719-3736 - 2002
James R. Berenson1, Bruce E. Hillner1, Robert A. Kyle1, K.M. Anderson1, Allan Lipton1, Gary C. Yee1,2, J. Sybil Biermann1
1From the American Society of Clinical Oncology, Health Services Research Department, Alexandria, VA.
2Pharmacy Practice

Tóm tắt

PURPOSE: To determine clinical practice guidelines for the use of bisphosphonates in the prevention and treatment of lytic bone disease in multiple myeloma and to determine their respective role relative to other conventional therapies for this condition. METHODS: An expert multidisciplinary Panel reviewed pertinent information from the published literature through January 2002. Values for levels of evidence and grade of recommendation were assigned by expert reviewers and approved by the Panel. Expert consensus was used if there were insufficient published data. The Panel addressed which patients to treat and when to treat them in the course of their disease. Additionally, specific drug delivery issues, duration of therapy, initiation of treatment and management of treatment of lytic bone disease was reviewed and compared with other forms of therapy for lytic bone lesions. Finally, the Panel discussed patient and physician expectations associated with this therapy for bony metastases, as well as public policy implications related to the use of bisphosphonates. The guidelines underwent external review by selected physicians, by the Health Services Research Committee members, and by the ASCO Board of Directors. RESULTS: The available evidence involving randomized controlled trials is modest but supports that oral clodronate, intravenous pamidronate, and intravenous zoledronic acid are superior to placebo in reducing skeletal complications. A reduction in vertebral fractures has consistently been seen across all studies. No agent has shown a definitive survival benefit. Intravenous zoledronic acid has recently been shown to be as effective as intravenous pamidronate. Because there are no direct comparisons between clodronate and pamidronate or zoledronic acid, the superiority of one agent cannot be definitively established. However, the panel recommends only intravenous pamidronate or zoledronic acid in light of the use of the time to first skeletal event as the primary end point and more complete assessment of bony complications in studies evaluating it. Additionally, clodronate is not available in the United States. The choice between pamidronate and zoledronic acid will depend on choosing between the higher drug cost of zoledronic acid, with its shorter, more convenient infusion time (15 minutes), versus the less expensive drug, pamidronate, with its longer infusion time (2 hours). CONCLUSION: Bisphosphonates provide a meaningful supportive benefit to multiple myeloma patients with lytic bone disease. However, further research on bisphosphonates is warranted, including the following: (1) when to start and stop therapy, (2) how to integrate their use with other treatments for lytic bone disease, (3) how to evaluate their role in myeloma patients without lytic bone involvement, (4) how to distinguish between symptomatic and asymptomatic bony events, and (5) how to better determine their cost-benefit consequence.

Từ khóa


Tài liệu tham khảo

10.1046/j.1365-2141.1998.01082.x

10.1182/blood.V98.13.3534

10.1182/blood.V98.13.3527

Kyle RA: Multiple myeloma: Review of 869 cases. Mayo Clin Proc 50: 29,1975-40,

10.1016/0360-3016(89)90008-4

10.1182/blood.V56.3.521.bloodjournal563521

10.1016/0002-9343(78)90522-3

10.1200/JCO.2000.18.6.1378

Canadian Task Force on the Periodic Health Examination: The periodic health examination: Canadian Task Force on the Periodic Health Examination. CMAJ 121: 1193,1979-1254,

10.1378/chest.95.1.2

Cook DL, Guyatt GH, Laupacis A, et al: Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 102: 305S,1992-311S, (suppl 4)

10.1002/(SICI)1097-0142(19971015)80:8+<1668::AID-CNCR17>3.0.CO;2-Y

10.1016/S0959-8049(97)10136-8

10.1001/archinte.1994.00420170079008

10.1200/JCO.2001.19.2.558

10.1016/S0002-9343(99)00062-5

10.1056/NEJM200102013440503

10.1001/jama.280.24.2077

10.1210/edrv.19.1.0325

10.1016/0009-9236(95)90245-7

10.1056/NEJM199602223340802

10.1200/JCO.1998.16.2.593

10.1093/jnci/93.7.534

10.1056/NEJM199612123352401

10.1093/jnci/93.7.488

10.1200/JCO.1993.11.1.59

10.1016/0140-6736(92)93075-X

10.1046/j.1365-2141.1998.00567.x

10.1200/JCO.1998.16.3.1218

10.1046/j.1365-2141.2001.02851.x

Rosen LS, Gordon D, Antonio BS, et al: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 7: 377,2001-387,

10.1016/0021-9681(81)90058-8

10.1046/j.1365-2141.1998.00695.x

10.1016/0221-8747(82)90013-3

Heim ME, Clemens MR, Queisser W, et al: Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma. Onkologie 18: 439,1995-448,

10.1002/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0

10.1200/JCO.1991.9.8.1397

Daragon A, Humez C, Michot C, et al: Treatment of multiple myeloma with etidronate: Results of a multicentre double-blind study—Groupe d’Etudes et de Recherches sur le Myelome (GERM). Eur J Med 2: 449,1993-452,

Fontana A, Herrmann Z, Menssen HD, et al: Effects of intravenous ibandronate therapy on skeletal related events (SRE) and survival in patients with advanced multiple myeloma. Blood 92: 106a,1998 (abstr)

10.1034/j.1600-0609.2000.065005331.x

10.1002/(SICI)1097-0142(20000101)88:1<6::AID-CNCR3>3.0.CO;2-D

Markowitz GS, Appel GB, Fine PL, et al: Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12: 1164,2001-1172,

10.2165/00002512-199812020-00007

10.1056/NEJM199803123381107

Ravn P, Bidstrup M, Wasnich RD, et al: Alendronate and estrogen-progestin in the long-term prevention of bone loss: Four-year results from the early postmenopausal intervention cohort study—A randomized, controlled trial. Ann Intern Med 131: 935,1999-942,

10.1146/annurev.med.50.1.237

Mundy GR: Bisphosphonates as cancer drugs. Hospital Practice (Office Edition) 34: 81,1999-84,

10.1182/blood.V87.11.4762.bloodjournal87114762

10.1001/jama.280.24.2077

10.1016/S0305-7372(96)90021-3

10.1016/S0959-8049(98)00277-9

10.1002/1097-0142(20010415)91:8<1487::AID-CNCR1156>3.0.CO;2-2

10.1016/S8756-3282(00)00271-4

10.1182/blood.V96.8.2697

10.1046/j.1365-2141.1997.8672495.x

10.1200/JCO.1998.16.12.3890

10.1002/1097-0142(19941201)74:11<2949::AID-CNCR2820741110>3.0.CO;2-Q

10.1007/s005200050218

Yazawa Y, Frassica FJ, Chao EY, et al: Metastatic bone disease: A study of the surgical treatment of 166 pathologic humeral and femoral fractures. Clin Orthopaed Rel Res ( 251): 213,1990-219,

10.1016/S0360-3016(97)00952-8

10.1016/0360-3016(92)90565-Y

10.1001/jama.1995.03530050068035

Bensinger W, Giralt S, Eary J, et al: Phase I-II study of 186 holmium-DOTP in combination with melphalan +/- total body irradiation (TBI) with autologous peripheral blood stem cell transplant (PBSCT) for patients with multiple myeloma. Proc Am Soc Clin Oncol 19: 9a,2000 (abstr 26)

10.1046/j.1365-2141.1999.01194.x

10.1111/j.1365-2141.1994.tb06730.x

10.1007/s005200100249

10.1200/JCO.2002.02.032

Thông tin
Thông tin xuất bản

American Society of Clinical Oncology (ASCO)

Tập 20 Số 17

3719-3736

Thông tin tác giả